Overexpression of specific HDAC isoforms observed in pancreatic cancer; HDAC inhibitors show anti-tumor effects in preclinical models. (Hai et al., 2021; Li et al., 2020). This evidence concerns the gene HDAC9 and familial pancreatic carcinoma.